The global cancer biomarkers market is experiencing a transformative growth phase driven by increasing cancer prevalence worldwide, rapid technological advancements in molecular diagnostics, and the growing shift toward precision medicine. Valued at approximately US$ 27.8 billion in 2025, the market is projected to reach over US$ 100.9 billion by 2036, expanding at a compound annual growth rate (CAGR) of 12.3% from 2026 to 2036.

Cancer biomarkers—biological molecules found in blood, tissue, or bodily fluids—play a critical role in detecting cancer at early stages, monitoring disease progression, predicting treatment response, and guiding personalized therapy decisions. As healthcare systems globally prioritize early diagnosis and targeted treatment strategies, cancer biomarkers have become central to modern oncology practice.

Rising Cancer Burden Driving Market Expansion

One of the primary forces fueling the cancer biomarkers market is the increasing global incidence of cancer. Aging populations, lifestyle changes, environmental exposure, and genetic predisposition are collectively contributing to a steady rise in cancer cases across both developed and emerging economies.

Healthcare systems are increasingly shifting their focus toward early detection, as early-stage diagnosis significantly improves survival rates and reduces treatment costs. Cancer biomarkers enable clinicians to identify molecular and genetic alterations associated with tumors, allowing timely and more effective intervention.

Governments and healthcare organizations are also expanding national cancer screening programs and investing heavily in oncology research, further strengthening demand for biomarker-based diagnostic solutions.

Technological Advancements Reshaping Cancer Diagnostics

Technological innovation remains a key catalyst for growth in the cancer biomarkers market. Breakthroughs in next-generation sequencing (NGS), liquid biopsy, proteomics, and multi-omics integration are revolutionizing cancer detection and monitoring.

NGS enables comprehensive analysis of genetic mutations at high speed and accuracy, allowing for identification of cancer-specific biomarkers that support targeted therapy selection. Meanwhile, liquid biopsy technologies—based on circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs)—offer minimally invasive alternatives to traditional tissue biopsies.

These advancements allow clinicians to:

• Detect cancer earlier and more accurately
• Monitor disease progression in real time
• Evaluate treatment response dynamically
• Reduce reliance on invasive procedures

Proteomics is also playing an increasingly important role by analyzing protein expression patterns and tumor biology, providing deeper insights into disease mechanisms.

Together, these technologies are significantly improving diagnostic precision and enabling the development of personalized treatment strategies.

Growing Role of Artificial Intelligence and Multi-Omics Integration

Artificial intelligence (AI) and machine learning are emerging as powerful tools in cancer biomarker discovery. AI-driven platforms are accelerating data analysis from genomic, proteomic, and clinical datasets, enabling faster identification of novel biomarkers and improving diagnostic accuracy.

Additionally, the integration of multi-omics approaches—combining genomics, proteomics, metabolomics, and transcriptomics—is transforming cancer research. This holistic approach provides a more comprehensive understanding of tumor biology and is expected to enhance precision oncology applications in the coming years.

Market Segmentation Insights

By Biomarker Type

The market is segmented into:

• Genetic biomarkers (including BRAF, ALK, BRCA1/2)
• Protein biomarkers (including HER2, PSA, CA-125, AFP, CA 15-3, and others)
• Cellular biomarkers (including circulating tumor cells and immune cells)
• Others (metabolic biomarkers, etc.)

Among these, protein biomarkers currently hold a significant share due to their widespread clinical use in cancer screening and monitoring.

By Cancer Type

Key cancer types include:

• Breast cancer
• Prostate cancer
• Ovarian cancer
• Colorectal cancer
• Liver cancer
• Thyroid cancer
• Others

Breast cancer dominates the market, accounting for approximately 37.3% share in 2025, driven by high global prevalence and extensive adoption of biomarkers such as HER2, BRCA, ER, PR, and Ki-67.

By End-User

Major end-users include:

• Diagnostic laboratories
• Biopharmaceutical companies
• Hospitals and specialty clinics
• Research and academic institutes

Biopharmaceutical companies are increasingly leveraging biomarkers for drug development, clinical trials, and companion diagnostics, making them a key growth segment.

Regional Outlook: North America Leads Global Market

North America dominates the global cancer biomarkers market with a 42.6% revenue share in 2025, supported by advanced healthcare infrastructure, high cancer prevalence, and strong presence of leading biotechnology and pharmaceutical companies.

The United States, in particular, is a major contributor due to:

• Strong R&D investments in oncology
• Favorable reimbursement policies
• Rapid adoption of advanced diagnostic technologies
• Expanding precision medicine initiatives

Europe follows closely, driven by increasing cancer screening programs and strong regulatory frameworks supporting biomarker-based diagnostics.

Meanwhile, Asia-Pacific, Latin America, and the Middle East are expected to witness the fastest growth during the forecast period due to:

• Improving healthcare infrastructure
• Rising cancer incidence
• Expanding access to diagnostic technologies
• Government-led cancer awareness initiatives

Competitive Landscape

The cancer biomarkers market is highly competitive, with several global players investing heavily in research and innovation. Key companies include:

• Illumina Inc.
• Abbott Laboratories
• Roche Diagnostics
• Siemens Healthineers
• PerkinElmer Inc.
• Bio-Rad Laboratories
• bioMérieux
• Merck KGaA
• Bio-Techne
• Quanterix
• Biocartis

These companies are focusing on strategic collaborations, product innovation, and expansion of biomarker testing portfolios to strengthen their market positions.

Recent developments include partnerships focused on AI-powered biomarker discovery, regulatory approvals for advanced genomic testing platforms, and expansion of companion diagnostic solutions.

Key Market Trends

Several key trends are shaping the future of the cancer biomarkers market:

• Increasing adoption of liquid biopsy for non-invasive cancer detection
• Growing use of AI and machine learning in biomarker discovery
• Expansion of companion diagnostics in targeted cancer therapy
• Rising integration of multi-omics approaches in clinical research
• Increasing collaboration between pharmaceutical and diagnostic companies
• Strong emphasis on early cancer screening programs globally

These trends are expected to significantly enhance diagnostic capabilities and improve patient outcomes over the forecast period.

Market Challenges

Despite strong growth potential, the market faces several challenges:

• High cost of biomarker discovery and validation
• Complex regulatory approval processes
• Variability in reimbursement policies across regions
• Difficulty in demonstrating consistent clinical utility
• Limited accessibility in low-income regions

However, ongoing technological advancements and increasing healthcare investments are expected to mitigate these challenges over time.

Growth Opportunities

Emerging markets present significant opportunities for expansion. Regions such as Asia-Pacific, Latin America, and the Middle East are witnessing rapid improvements in healthcare infrastructure and increasing adoption of advanced diagnostic technologies.

Additional opportunities include:

• Expansion of early-stage cancer screening programs
• Growth in non-invasive diagnostic methods
• Increasing partnerships between biotech and pharmaceutical companies
• Rising demand for personalized medicine approaches

Conclusion

The global cancer biomarkers market is on a strong upward trajectory, driven by technological innovation, increasing cancer burden, and the global shift toward precision medicine. With the market expected to exceed US$ 100.9 billion by 2036, cancer biomarkers are set to play an increasingly vital role in early detection, treatment personalization, and disease monitoring.

As AI, genomics, and liquid biopsy technologies continue to evolve, the market is expected to witness accelerated innovation, improved diagnostic accuracy, and expanded global adoption, ultimately transforming the future of oncology care.